(MIRM) Mirum Pharmaceuticals, Inc. Business Model Canvas Research

Specialty pharmacies and distributors are key for Mirum Pharmaceuticals, Inc. because its rare-disease therapies use limited channels for access, prior authorization, shipment tracking, and refill management. With 2 commercial products for chronic pediatric liver disease, these partners help speed patient onboarding and keep therapy continuity high.

• Handle prior auth
• Track shipments
• Manage refills
• Support onboarding

Patient advocacy organizations help Mirum Pharmaceuticals, Inc. educate families, spot undiagnosed patients, and raise caregiver awareness, which matters in rare diseases where diagnosis can take 5+ years and affect about 300 million people worldwide. They also build trust around new therapies by giving patients a credible voice.

• Disease education
• Patient identification
• Caregiver awareness
• Trust for new treatments

Mirum Pharmaceuticals, Inc. runs manufacturing and supply planning to match forecast demand, quality checks, and inventory levels for its oral rare-disease medicines. That matters because even brief gaps can interrupt treatment, so supply needs to stay aligned with patient use and clinical trial demand.

• Plan production around forecasted patient demand
• Keep quality control tight at every batch
• Hold enough inventory to avoid interruptions

Mirum Pharmaceuticals, Inc. uses medical affairs to publish scientific materials, answer medical questions, and support congress activity across its rare-disease franchise, which includes 3 marketed therapies. In rare pediatric diseases, long-term safety and real-world evidence matter because trials are small, so these activities help build trust with specialists and payers.

• Scientific content for specialists

• Medical inquiry response support

• Congress and data-sharing activity

• Real-world and long-term safety evidence

Mirum Pharmaceuticals, Inc. relies on clinical and regulatory data as a core intangible asset: study results, safety data, and real-world evidence help secure approvals, support label expansion, and build prescriber trust in rare, complex diseases. This matters in a small market where Mirum’s approved therapies, including Livmarli for Alagille syndrome and PFIC, depend on strong evidence to defend differentiation.

• Supports FDA approvals and label growth
• Backs safety and efficacy claims
• Raises prescriber confidence
• Helps win in rare-disease niches

Mirum Pharmaceuticals, Inc. relies on field teams, patient support, and market access functions to reach specialists and manage reimbursement for its rare-disease therapies. Its Foster City, California headquarters anchors corporate operations and decision-making.

• Field teams support specialist reach
• Patient support eases reimbursement steps
• Headquarters: Foster City, California

Mirum Pharmaceuticals, Inc. is spreading its liver-disease pipeline across PFIC, Alagille syndrome, biliary atresia, ICP, and PSC, so one asset can reach more patients and more labels. That multi-indication setup can extend lifecycle value and create several commercial wins from the same scientific base.

• Five disease targets, one platform.
• More labels can lift lifetime revenue.
• Clinical wins can support commercial growth.

Mirum Pharmaceuticals pairs therapy development with access support, which matters in rare disease care where diagnosis can take 4.8 years on average and patients often need help with insurance and treatment setup. This specialty model turns the drug into a full service offer, not just a prescription.

• Speeds diagnosis and access
• Helps with insurance hurdles
• Supports ongoing treatment use

Mirum Pharmaceuticals, Inc. must field detailed questions from clinicians and pharmacists, because orphan-disease care often serves fewer than 200,000 patients in the U.S. Medical information teams help confirm dose, safety, and use, which matters in complex therapies like a 2025 company with approved rare-disease medicines and a high-touch support model.

• Supports safe, appropriate use
• Answers technical clinician questions
• Fits rare-disease complexity

Mirum Pharmaceuticals, Inc. serves chronic cholestatic disorders where therapy and lab monitoring can last for years, so customer relationships must support refills, follow-up, and adverse-event checks. This steady contact helps keep patients on treatment and builds trust in diseases like PFIC and Alagille syndrome, which often need long-term care.

• Supports refill continuity
• Tracks safety and labs
• Reinforces long-term trust

Mirum uses targeted field sales and medical teams instead of broad consumer ads, which fits an orphan-disease model where prescribers are few and specialist-led. The field force educates clinicians on approved uses, while medical teams support the scientific dialogue that drives access and adoption in rare diseases.

• Focuses on specialist prescribers
• Uses scientific, not mass-market, outreach
• Matches orphan-disease economics

Mirum Pharmaceuticals, Inc. uses digital patient support to speed education, enrollment, and treatment reminders, which matters in rare pediatric disease where caregivers often manage daily dosing and follow-up. These tools extend support beyond the clinic visit and can keep families engaged between appointments.

• Helps with education and enrollment
• Supports caregiver reminders outside clinic

Mirum Pharmaceuticals, Inc. is broadening Volixibat’s customer base from rare pediatric cholestatic disease to adult specialists treating intrahepatic cholestasis of pregnancy (ICP), which affects about 0.2% to 2% of pregnancies, and primary sclerosing cholangitis (PSC), a rare adult liver disease. That adds obstetrics and hepatology settings, so the addressable market is no longer tied mainly to pediatric centers.

• ICP: pregnancy-focused OB care
• PSC: adult hepatology care
• Expands beyond pediatric disease
• Different sites, prescribers, payers

Hepatology specialists make the Rx call, while payers decide if Mirum Pharmaceuticals, Inc. products get covered, so both groups shape rare-disease uptake. This matters in cholestatic liver disease, where access hinges on clear clinical value and affordable net price, with payers often using prior auth and step edits.

• Specialists drive diagnosis and prescribing
• Payers control formulary access and reimbursement
• Mirum must prove outcomes and value

Manufacturing and quality are a material cost for Mirum Pharmaceuticals, Inc. because oral specialty drugs still need batch testing, packaging, release checks, and tight inventory control. In chronic therapy, even one supply break matters, so continuity has to stay high across every lot and shipment.

That makes quality systems and supply-chain management core cost drivers, not back-office work. Mirum Pharmaceuticals, Inc. must fund cGMP controls, stability testing, and safety stock to keep patients on therapy without interruption.

• Drug production and release testing
• Packaging and cold-chain handling
• Strict quality and inventory control
• Continuous supply for chronic use

Mirum Pharmaceuticals, Inc.’s general and administrative cost covers finance, legal, human resources, and executive leadership, plus public-company audit and reporting work. For a biotech with rising regulatory burden, these costs usually climb with headcount and compliance load, and Mirum’s FY2025 filing should be used to pin the exact spend and its share of operating costs.

• Finance, legal, HR, and leadership
• Audit and SEC reporting costs
• Scales with growth and regulation

Mirum Pharmaceuticals, Inc. can lift revenue by adding LIVMARLI and other products to more countries, because each new launch needs local approval and payer reimbursement. With 2025 net product sales of about $300 million, even small country rollouts can widen the addressable market fast.

• More countries = more launch chances
• Regulatory approval is a gate
• Reimbursement drives real sales
• Broader reach can expand TAM

Mirum Pharmaceuticals records net product revenue after rebates, discounts, chargebacks, and returns, so the reported number is the true operating base, not gross billing. In 2025, this net revenue line remained the core rare-disease sales driver for Livmarli and Ctexli, which is how specialty pharma usually reports recognized revenue.

• Revenue is booked net of deductions
• Rare-disease sales are the base